KalVista Pharmaceuticals, Inc. (KALV) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
High costs for multi-year trials and patent barriers define entry into the rare immune pathology sector. The historical EV/EBITDA chart for KalVista Pharmaceuticals (KALV) on the GURU.Markets platform visualizes the market consensus, where the current mark equals 0.00. KalVista Pharmaceuticals (KALV) adheres to bioethical norms and ESG standards in its laboratories, while the anticipation of trial results for its oral therapy for edema serves as the primary growth driver.
KalVista Pharmaceuticals, Inc. - analytical breakdowns and key metrics (KALV)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity KalVista Pharmaceuticals|KALV - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital kalvista.com|KALV - Company Cumulative Debt|Debt to Book Capitalization Ratio KalVista Pharmaceuticals|KALV - Company Long-Term Debts|Company Short-Term Debts KalVista Pharmaceuticals|Quick Liquidity kalvista.com
- business earnings and investment ratios data:
KALV - Company Net Income|Future Profit KalVista Pharmaceuticals|KALV - Price to Earnings Ratio|Forward P/E Multiple KalVista Pharma|KALV - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization KalVista Pharmaceuticals Inc|KALV - Operating income before deduction of amortization|Net earnings per share for the last 12 months KalVista Pharmaceuticals|KALV - Earnings per share for the last four quarters|Quarterly EPS earnings growth kalvista.com|KALV - Earnings growth in current year|Expected earnings per share growth for next year KalVista Pharmaceuticals
- sales and revenue data:
Initial company analysis:KALV (KalVista Corp)
The EV/EBITDA multiple reflects the total value of the business, including net debt, relative to its operating income, allowing investors to assess the payback period of assets without tax and depreciation distortions. By analyzing fluctuations in the EV/EBITDA multiple, one can identify the undervaluation of KalVista Pharmaceuticals (KALV), whose unique molecule synthesis model ensures high margins and global scalability with minimal costs.
Competitors of KalVista Pharmaceuticals
EV/EBITDA Multiple ARGX (argenx.com)|Total Company Value to Operating Income Before Depreciation Ratio biontech.de (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ADMA Biologics Inc (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist Corp (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant, Inc.|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple grifols.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies Corp (ADPT)|Celldex Therapeutics, Inc. - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (auriniapharma.com)|BioCryst Pharmaceuticals Inc (BCRX) - Company Value to EBITDA|VERA: Enterprise Value to EBITDA Ratio|DNTH (Dianthus Therapeutics) - Enterprise Value to Operating Income Before Depreciation|PHVS: EV/EBITDA Multiple|ABCL (AbCellera Biologics Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio TRML|Company Value to EBITDA Intrexon PGEN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pharming Group N.V. (PHAR)|Enterprise Value to Operating Income Before Depreciation Ratio NKTR|EV/EBITDA Multiple UPB (Upstream Pharma)|Total Company Value to Operating Income Before Depreciation Ratio Zenas Biopharma, Inc. (ZBIO)|IMNM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Gossamer Corp (GOSS) - Enterprise Value to EBITDA Ratio|Septerna (SEPN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|pieris.com - Business Value to Operating Income Before Depreciation|SVRA (Savara Inc) - EV/EBITDA Multiple|RIGL: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANAB|ATXS (Astria Pharma) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization enGene Holdings Inc. ENGN|EV/EBITDA Multiple RAPT Therapeutics Inc. RAPT|Aerovate Therapeutics - EV/EBITDA Multiple|Company Value to EBITDA Aclaris Therapeutics Inc.|Kyverna (KYTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Tiziana Life Sciences (TLSA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cabaletta Bio Inc.|Ventyx Biosciences (VTYX) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple THTX|EV/EBITDA Multiple Avalo Therapeutics Inc. (AVTX)|EV/EBITDA Multiple ELDN (eledon.com)|AGEN - Enterprise Value to EBITDA Ratio|CLYM: Enterprise Value to EBITDA Ratio|ZURA (Zura Bio Limited) - Enterprise Value to Operating Income Before Depreciation|ATYR: EV/EBITDA Multiple|Adagene (ADAG) - EV/EBITDA Multiple|IMA (ikenaoncology.com) - EV/EBITDA Multiple|shattucklabs.com (STTK) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Equillium Inc (EQ)|Connect Pharma - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Immunic, Inc. IMUX|ATRA - Enterprise Value to EBITDA Ratio|IFRX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|XFOR: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ACET: EV/EBITDA Multiple|Celularity Corp (CELU) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization INmune Bio|Barinthus Biotherapeutics plc (BRNS) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple KZR|SABS: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple AKTX (Akari Therapeutics, Plc)|ENLV (Enlivex Therapeutics, Ltd.) - Company Value to Operating Income Before Depreciation Ratio|QTTB: Enterprise Value to EBITDA Ratio|GOVX - EV/EBITDA Multiple|Edesa Biotech Corp (EDSA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IBIO - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization carismatx.com|XTLB: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bolt Biotherapeutics Inc. (BOLT)|HCWB (HCW Biologics) - Business Value to Operating Income Before Depreciation|Aptevo Therapeutics - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple AIM ImmunoTech Inc. AIM|Aditxt Inc. - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation GRI (GRI Bio, Inc.)|XORTX Therapeutics Inc (XRTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio ReShape Lifesciences|Enterprise Value to EBITDA Ratio REVB|Indaptus Corp (INDP) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization scinai.com (SCNI)|Enterprise Value to EBITDA Ratio CalciMedica CALI|EV/EBITDA Multiple AFMD (affimed.com)|Allakos Inc. (ALLK) - Company Value to EBITDA|HOOKIPA - EV/EBITDA Multiple|IGMS (igmbio.com) - Enterprise Value to Operating Income Before Depreciation|ITOS (iTeos) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation OCEA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TC BioPharm|Third Harmonic Bio Inc. (THRD) - Total Company Value to Operating Income Before Depreciation Ratio
